Jeffrey S. Miller, MD, University of Minnesota, Minneapolis, MN, outlines recent advances in the use of off-the-shelf, engineered induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells for the treatment of glioblastoma. Prof. Miller discusses challenges that have been overcome, such as dosing limitations, as well as the rationale behind the creation of these NK cells. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.